Why Hims & Hers (HIMS) rose 3.35%
Hims & Hers (HIMS) rose 3.35% on August 5, 2026 — Lilly's blockbuster lifts GLP-1 / obesity peers.
What happened
Eli Lilly easily topped quarterly estimates and raised 2026 revenue guidance on surging Zepbound and Mounjaro sales, triggering a broad GLP-1 / Obesity theme rally that lifted Hims alongside its peers.
Why it moved
Lilly's beat and raise validate GLP-1 demand tailwinds and supply normalization — the macro backdrop for all obesity-therapy players; Hims benefits from the rising tide of category enthusiasm and reduced narrative risk…
Why it matters
Hims is a secondary beneficiary of the GLP-1 / Obesity supercycle recovery — Lilly's earnings win proves the narrative is intact and durability fears are overblown, restoring conviction in the entire theme and lifting…
What would break the thesis
If Hims' own earnings or guidance disappoint in coming quarters, or if Lilly's supply-chain caution resurfaces, Hims will lose the sympathy support and re-test lows.